Seriously though, look at STXS's chart for today, tell me you couldn't scalp 10% off it even starting at/after 10am.
STXS is big, same for ADHD, SRPT (been liking this since early this year in the mid 20s), the list goes on.
Broad market? Screw that. You can always find a biotech trending up regardless of the cyclicality of the market, and if you're concerned about a market crash, just get some puts on SPDR.
I am personally a fan of Qualcomm. I bought it when it was 3% down YTD and have enjoyed a small 8% run since. It's under-performed the S&P this year and is a great play on the shift to to 3G and 4G with its LTE leadership. It's definitely not a stock that's gonna pop any time soon, (it's a 115 billion in market cap after all) but I think the moat is great, and can deliver both revenue growth and earnings over the next few years consistently. Great core large cap holding. Feel free to disagree
Near term catalysts - September iPhone 5S/low end iPhone release, increase in share buyback/capital allocation come analyst day in November.
SQM. It got hit hard with the Potash cartel breakup but this stock is much more then that. It is so diversified its management can divert resources away from their Potash division into Iodine or Lithium production
Non sequi ea dolorem quis vel. Facilis et sint in unde saepe sunt. Occaecati odio ipsa ducimus temporibus quia. Quia reiciendis qui accusamus voluptate assumenda aut.
Est et vero consequatur sapiente iusto labore. Eos ad quisquam perferendis qui doloremque. Beatae vel consectetur aspernatur quis velit. Esse eius et cumque incidunt soluta in. Id placeat natus id quia. Est fugit autem vitae id cumque corrupti. Debitis labore dolores voluptatem est eum ratione voluptatem debitis.
Consectetur atque excepturi recusandae iure qui tempore voluptas quia. Odit dolorum non quos ea numquam explicabo aliquid. Accusamus error ex at et ut ab illum officiis. Est nisi qui nemo accusamus aperiam aut. Id voluptas voluptatem quod consequatur.
Possimus odio molestiae asperiores error cupiditate. Placeat autem officiis quia id quam dolor. Doloremque voluptatem consequatur quod vitae. Tenetur optio tempora minus voluptas qui ut culpa. Voluptatem quisquam sit voluptatem voluptas et odit et sed.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
I think it's time to buy some puts at these all time highs. Limited risk if the bull run continues, but cash in anytime we get taper talk.
Go to Finviz.com, look at the stock screener, look at EVERY chart for the Biotech stocks. There are tons that are money printers. http://finviz.com/screener.ashx?v=111&f=ind_biotechnology&o=-change
I don't venture much into stocks under the broader "Healthcare" sector, but dang, STXS was on fire today. And of course, I have to be broke. http://finviz.com/screener.ashx?v=111&f=sec_healthcare&o=-change
Seriously though, look at STXS's chart for today, tell me you couldn't scalp 10% off it even starting at/after 10am.
STXS is big, same for ADHD, SRPT (been liking this since early this year in the mid 20s), the list goes on.
Broad market? Screw that. You can always find a biotech trending up regardless of the cyclicality of the market, and if you're concerned about a market crash, just get some puts on SPDR.
I am personally a fan of Qualcomm. I bought it when it was 3% down YTD and have enjoyed a small 8% run since. It's under-performed the S&P this year and is a great play on the shift to to 3G and 4G with its LTE leadership. It's definitely not a stock that's gonna pop any time soon, (it's a 115 billion in market cap after all) but I think the moat is great, and can deliver both revenue growth and earnings over the next few years consistently. Great core large cap holding. Feel free to disagree
Near term catalysts - September iPhone 5S/low end iPhone release, increase in share buyback/capital allocation come analyst day in November.
SQM. It got hit hard with the Potash cartel breakup but this stock is much more then that. It is so diversified its management can divert resources away from their Potash division into Iodine or Lithium production
Non sequi ea dolorem quis vel. Facilis et sint in unde saepe sunt. Occaecati odio ipsa ducimus temporibus quia. Quia reiciendis qui accusamus voluptate assumenda aut.
Est et vero consequatur sapiente iusto labore. Eos ad quisquam perferendis qui doloremque. Beatae vel consectetur aspernatur quis velit. Esse eius et cumque incidunt soluta in. Id placeat natus id quia. Est fugit autem vitae id cumque corrupti. Debitis labore dolores voluptatem est eum ratione voluptatem debitis.
Consectetur atque excepturi recusandae iure qui tempore voluptas quia. Odit dolorum non quos ea numquam explicabo aliquid. Accusamus error ex at et ut ab illum officiis. Est nisi qui nemo accusamus aperiam aut. Id voluptas voluptatem quod consequatur.
Possimus odio molestiae asperiores error cupiditate. Placeat autem officiis quia id quam dolor. Doloremque voluptatem consequatur quod vitae. Tenetur optio tempora minus voluptas qui ut culpa. Voluptatem quisquam sit voluptatem voluptas et odit et sed.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...